

1 **Title: Weight Management in Primary Care: Scoping Review for Promising Interventions**

2
3 **Authors:**

4 Olivia O'Young¹

5 Paula Brauer¹

6 Dawna Royall¹

7 Laura Bjorklund¹

8 John Dwyer¹

9 A. Michelle Edwards¹

10 Tracy Hussey²

11 Nick Kates²

12 Heidi Smith³

13 Ross Kirkconnell³

14 1) University of Guelph, Canada

15 2) Hamilton Family Health Team, Hamilton, Canada

16 3) Guelph Family Health Team, Guelph, Canada

17

18 Olivia O'Young, MSc, RD

19 University of Guelph,

20 50 Stone Rd. E, Guelph, ON N1G 2W1

21 olivia.oyoung@gmail.com

22

23 Paula Brauer, PhD, RD,

24 University of Guelph,

25 50 Stone Rd. E, Guelph, ON N1G 2W1

26 pbrauer@uoguelph.ca

27

28 Dawna Royall, MSc, RD,

29 University of Guelph,

30 50 Stone Rd. E, Guelph, ON N1G 2W1

31 phcnutr@uoguelph.ca

32

33 Laura Bjorklund, MSc, RD

34 University of Guelph,

35 50 Stone Rd. E, Guelph, ON N1G 2W1

36 lbhouina@gmail.com

37

38 John J.M. Dwyer, PhD

39 University of Guelph,

40 50 Stone Rd. E, Guelph, ON N1G 2W1

41 dwyer@uoguelph.ca

42

43 A. Michelle Edwards, PhD, MLIS

44 University of Guelph,

45 50 Stone Rd. E, Guelph, ON N1G 2W1

46 edwardsm@uoguelph.ca

47
48 Tracy Hussey, MSc, RD
49 Hamilton Family Health Team,
50 10 George St., 3rd Floor, Hamilton, ON L8P 1C8
51 tracy.hussey@hamiltonfht.ca

52
53 Nick Kates, MB, BS, FRCP(C)
54 McMaster University
55 1280 Main St. W. Hamilton, ON L8S 4L8
56 nkates@mcmaster.ca

57
58 Heidi Smith
59 Formerly Guelph Family Health Team
60 Currently Health and Performance Centre
61 University of Guelph
62 smith@uoguelph.ca

63
64 Ross Kirkconnell, MSc
65 Guelph Family Health Team
66 Suite 207, 55 Wyndham St N, Guelph, ON N1H 7T8
67 ross.kirkconnell@guelphfht.com

68
69
70 **Contact Information for corresponding author:**
71 Paula Brauer, PhD, RD
72 Email: pbrauer@uoguelph.ca

73
74 **Running head: Obesity services review in primary care**
75

76 **Abstract**

77 **Background** As more primary care (PC) organizations are working to better address obesity
78 issues, it becomes important to identify and characterize the key elements of the most effective
79 lifestyle interventions when offered in the context of overall medical management. Studies
80 that met pre-defined criteria for clinical relevance that had been conducted in PC settings were
81 narratively reviewed for promising approaches.

82 **Methods** Search terms from three concepts (obesity/overweight, non-drug treatments, and PC
83 setting) were used to search PubMed, CINAHL, Cochrane CENTRAL, and Science Citation
84 Index Expanded. Primary studies of any study design, published between 2003 and March
85 2012, were grouped by major disease/condition and assessed for pre-defined clinically
86 relevant changes in intermediate and clinical outcomes. To aid in interpretation, study design
87 and quality were assessed and key features of the studies summarized. Details of
88 interventions by provider background, training for the intervention and delivery channel were
89 catalogued.

90 **Results** The search yielded 280 unique intervention studies (including controlled clinical trials
91 and pre-post studies), of which 156 (56%) were somewhat or very likely to be conducted in
92 representative groups and had at least one clinically relevant change in an intermediate marker
93 or disease incidence. Nearly half (46%) were diabetes treatment studies. Overall, only 19
94 studies of the 68 (28%) relevant studies in adults (excluding pregnancy) that assessed weight
95 change achieved a mean weight loss of 3% or 1 BMI unit in the intervention group. Only in
96 prediabetes and metabolic syndrome was modest weight loss associated with a decrease in
97 diabetes incidence. The most successful interventions intensified lifestyle interventions
98 through a combination of increased physician efforts, additional providers, protocols for

99 management, and a range of additional resources, mentoring and performance monitoring.

100 **Conclusions** This review of diverse implementation studies conducted in primary care
101 confirmed that the most effective lifestyle programs can achieve modest changes in body
102 weight in some clinical subgroups. Such modest changes are clinically relevant in the
103 prediabetes/metabolic syndrome subgroup. The most promising studies provided insights to
104 inform further implementation studies. Additional methodological work is also needed to
105 determine best approaches for reviews of effectiveness of such complex interventions.

106

107 **Keywords:** patient care management; primary health care; delivery of health care; overweight;
108 health behavior

109

110 **Background**

111 Primary care (PC) services in Canada and other countries with comparable health care
112 systems are being challenged to implement lifestyle services (i.e., diet, physical activity, other
113 behaviour change and combinations of these) to prevent and treat obesity across the life cycle.
114 Several guidelines groups have promoted new lifestyle services in PC [1,2]. If services are to be
115 increased, they will need to be integrated with the medical services already offered, such as
116 prenatal care and management of common chronic conditions, like cardiovascular diseases
117 (CVD). As noted by an Australian PC obesity research group, there is only sparse evidence on
118 how results from clinical trials “can be translated into routine practice, and what systems may be
119 necessary to ensure widespread adoption” [3]. Review of the current evidence is a first step to
120 designing and testing new services in PC.

121 Obesity prevention and treatment are highly relevant to PC as the prevalence of excess

122 body weight has increased among both children and adults, and the associated common chronic
123 conditions, notably diabetes, CVD and some cancers, are commonly treated in PC [4].
124 Substantial minorities of the adult population have prediabetes, hypertension and/or
125 dyslipidemia. A significant minority of adults, (19% of adult Canadians (18+ years) and 40% of
126 those 60+ years [5]), meet criteria for the cardiometabolic syndrome (MetS) (hypertension,
127 visceral adiposity, dyslipidemia and hyperglycemia) and are at twice the risk of CVD, compared
128 to those without that combination of risk factors [6]. Among large randomized clinical trials, the
129 Diabetes Prevention Program (DPP) in the United States was notable in showing that lifestyle
130 change was effective in reducing the incidence of diabetes [7,8], but most studies have failed to
131 reduce mortality. The majority of care for all these conditions occurs in PC.

132 A number of systematic and other reviews of randomized clinical trials in specific
133 diseases and for specific types of interventions have already been completed [9-11]. In brief, the
134 majority of the current evidence base has been developed from studies conducted among
135 volunteers from specialty clinics or in the community and then assessed for “relevance” to the
136 PC setting, as was done in a recent review by the United States Preventive Services Task Force
137 (USPSTF) [10]. Study selection criteria have varied widely. Key features of lifestyle
138 interventions also vary widely and there are currently no broadly accepted ways of describing
139 interventions.

140 A new review was therefore planned to identify promising approaches across the life
141 span and spectrum of obesity prevention and treatment in PC. Various approaches to systematic
142 review were considered, recognizing that methods are evolving rapidly [12-14]. Overall, the goal
143 was to identify lifestyle studies conducted within PC, and then use quality assessment to interpret
144 the results and identify potentially promising intervention components that could be trialed. Since

145 many evaluations in practice have pre-post designs, these were not excluded, if they met other
146 criteria. The approach was aggregative rather than conceptual, and was intended to privilege
147 generalizability over internal validity. Methods were adapted from the Cochrane Collaboration
148 [15]. Therefore, documentation of the search strategy, screening and selection criteria, use of dual
149 reviewers and the assessment of the quality of evidence of all studies were planned from the
150 outset. In contrast to typical systematic reviews, however, multiple populations, interventions and
151 study designs were to be reviewed using the same review process. A priori, criteria for clinically
152 relevant change were established to focus efforts on identifying the most promising approaches.

153 **Methods**

154 **Designing the Search Strategy - Search Terms and Phrases**

155 A medical librarian with expertise in systematic reviews created a search strategy specific
156 to each database. The search strategy for each database is shown in Additional file 1. Each
157 database was searched using terms for three distinct concepts: obesity and overweight, non-drug
158 treatments, and PC setting.

159 **Included Electronic Databases**

160 The electronic databases PubMed, CINAHL, Cochrane CENTRAL, and SCI-Expanded
161 were searched for studies in English between January 2003 and March 2012. The timeframe was
162 chosen to identify studies completed since a previous search for our group done by the Evidence-
163 based Practice Centre at McMaster University [16]. All retrieved citations were exported,
164 compiled and organized (including removal of duplicates) into one Reference Manager 12 file
165 (<http://www.refman.com>).

166 **Inclusion Criteria for Study Selection**

167 **Types of Participants**

168 Age was not limited and the conditions of interest selected were overweight, obesity or
169 any obesity-related co-morbid conditions (e.g., type 2 diabetes, hypertension, dyslipidemia, or
170 CVD), where obesity prevention or treatment was relevant to manage the condition. Body
171 weight status was as recorded by authors and followed one of the international definitions.
172 Studies limited to a small subset of patients (<20 patients per group) were excluded.

173 **Types of Settings**

174 The study had to have been conducted in PC practice or in other settings (e.g., private
175 practice, community centre, pharmacy) if the intervention could be replicated in PC. Thus,
176 studies of cardiac rehabilitation or studies where volunteers were solicited by advertisements in
177 waiting rooms or newspapers were excluded (see Additional file 2).

178 **Types of Study Designs**

179 Primary studies of any research design were selected in screening; however, only pre-
180 post and stronger study designs (i.e. randomized controlled trials (RCT) or controlled clinical
181 trials) were reviewed in detail. Primary studies referenced from reviews (systematic or
182 narrative), guidelines or grey literature were included if they met the criteria.

183 **Types of Interventions and Outcome Measures**

184 The studies had to include a lifestyle component (i.e., discuss diet and/or physical
185 activity) in the intervention description, even if focused on overall medical management of the
186 relevant condition. Studies could be selected if they reported weight or body mass index (BMI,
187 kg/m²) but did not discuss details of the lifestyle therapy. The purpose of this last criterion was
188 to ensure the inclusion of the broader self-management studies for chronic conditions that usually
189 included some form of diet and exercise component.

190 A priori, criteria for clinically relevant change were established, recognizing the rarity of

191 studies that report on disease incidence and/or mortality. All studies that reported disease
192 incidence, prevalence or mortality were reviewed. Clinical relevance criteria for intermediate
193 indicators were set by the research team after review of current practice guidelines (see Table 1).

194 **Study Selection Process and Quality Assessment**

195 Two researchers reviewed all titles and abstracts; any article marked for inclusion by either
196 went on to full text review. Full text review, quality assessment and data abstraction were done by
197 two people who resolved any disagreements by discussion.

198 A title and abstract screening tool, as well as a full-text screening tool were developed
199 based on the participants, setting, intervention and outcomes measures, and specific exclusion
200 criteria (Additional file 2). A coding manual was also developed to improve consistency among
201 reviewers.

202 During the full-text screening process, relevant qualitative studies, descriptions of
203 organizational innovations and reviews were put aside and references of these articles were
204 screened by one researcher based on the title.

205 Quality assessment was completed in duplicate from the primary methodology paper for
206 each study. The Quality Assessment Tool for Quantitative Studies (public health) was used to
207 assess risk of bias, given the interest in multiple study designs (section 21.4) [15]. As a check on
208 the initial selection of studies, only studies that were **somewhat or very likely** to be
209 representative of the target population according to Question 1 of the tool, were considered
210 further.

211 **Summary Table Preparation**

212 Study data for all aspects of interventions and results were entered into an Excel database
213 for further review and selection of those achieving clinically relevant change in one or more of

214 the selected criteria. Studies were categorized according to health condition, study design and
215 baseline levels of selected clinical indicators, where relevant, since participants with more
216 extreme levels might respond to a greater degree than those with less extreme baseline levels
217 (regression to the mean). Lifestyle only versus comprehensive management studies were
218 considered together. Interventions were described according to providers' background, the
219 degree of description of any training provided and the delivery channels used. Weight or BMI
220 changes were described separately. Studies not meeting clinical criteria or identified with
221 selection bias were also catalogued.

222 **Results**

223 **Included Studies**

224 The initial search yielded 48,830 titles and abstracts to be screened. Of these, 1726 (4%)
225 met the initial eligibility criteria and were further reviewed (full-text screen) (Figure 1). An
226 additional 91 citations were handpicked (from reviews or citations which were part of a larger
227 study) and were screened. When 1817 full text papers were reviewed for relevance to PC, 1162
228 (64%) were excluded. Of the remaining, 280 unique intervention studies (428 citations) were
229 included and underwent full text review, and 156 (56%) met criteria for representativeness and
230 had at least one relevant change in a clinical indicator or reported disease incidence or mortality.

231 Geographically, US-based studies dominated (43%), followed by the UK (15%),
232 Netherlands (8%), Australia (5%), and Canada (4%). The recent publication of several multi-
233 country European studies, while small in number, is important as they involve much larger
234 numbers of subjects across differing models of PC practice (2%) (Figure 2). The remaining 31
235 studies were conducted in a range of countries.

236 All studies were categorized into nine unique groups of comparable studies, as shown in

237 Figure 3. Most prominent were the 128 studies (46%) of type 2 diabetes treatment, followed by
238 44 studies (16%) among people at risk for or who already had clinical CVD. Studies of lifestyle
239 change for health promotion and weight loss as a primary focus were put together (13%), with
240 studies specifically focused on prediabetes or MetS also grouped (9%). Four tables are provided
241 for each of the nine groups (Tables 2-5 for prediabetes/MetS and Additional files 3 to 10 for the
242 other groups): a summary of the clinically relevant studies, a description of the interventions,
243 reported weight or BMI changes, and the studies that had been screened out.

244 Among the 156 studies with at least one clinically relevant change, only three among the
245 25 prediabetes/MetS studies achieved significant declines in prevalence of MetS or incidence of
246 diabetes, a key clinical outcome [19, 24, 28] (Table 2). Only two studies (Griffin et al [17] and
247 Delaney et al [18]), assessed CVD incidence and/or mortality and neither showed a decline
248 (Additional files 3 and 4). Only four clinically relevant studies were ranked as being of high
249 methodological quality (Bo et al., [19], Griffin et al. [17] Davies et al. [20], Delaney et al. [18]
250 (Table 2, Additional files 3 and 4).

251

252 **Overall Results on Changes in BMI or Body Weight**

253 Nineteen of the 68 adult studies that assessed body weight achieved losses of 3% or 1
254 BMI unit in the intervention groups (Table 4 and Additional files 3 to 7 and Additional file 9).
255 Other outcomes like physical fitness or quality of life were not routinely assessed. Mean loss
256 was close to the predefined criterion in 18 of 19 studies. Only the Iori et al. group [21] in Italy
257 achieved greater mean loss, but their study may have captured only weight loss among the most
258 successful patients. A large number of practices (n=228) were involved and physicians focused
259 on weight loss among those with BMI \geq 27; many of whom had CVD risk factors or clinical CVD

260 [21]. Each physician submitted 10 patients and 6-month changes were reviewed. About 70%
261 returned for the 6-month visit. Among returnees, weight declined by a mean of 5%.

262 Review by providers' background, training, and delivery channels used in the 19 most
263 effective studies did not reveal any one group of key strategies that could be identified as
264 important to successful implementation of services (Table 3 and Additional files 3 to 7 Tables 3-
265 2, Table 4-2, Table 5-2, Table 6-2 and Table 7-2). All successful interventions involved
266 intensification of services using behaviour change counselling principles over longer periods of
267 time to address lifestyle in the context of overall medical management, consistent with the
268 findings of other reviews [10,22].

269 Multiple groups have shown that lifestyle therapy can prevent diabetes [23], so these
270 studies were reviewed in detail to identify possible promising approaches. Results for other
271 diseases and conditions are available as Additional files 3-10. Only the most promising studies
272 from these other diseases and conditions are narratively described.

273

274 **Prediabetes /Metabolic Syndrome**

275 The nine studies with relevant changes are shown in Table 2. There were five randomized
276 controlled trials (RCTs), and four one-group cohorts, with two reporting on MetS/prediabetes
277 prevalence and three on diabetes incidence. Table 3 shows intervention strategies, while Table 4
278 provides detail on study length and BMI/weight changes. Table 5 summarizes studies that did
279 not meet criteria for clinically relevant change or were unlikely to be representative

280 The three studies reporting on diabetes incidence are reviewed first. The cohort report by
281 Saaristo et al. [24] from Finland on a national program (FIN-D2D) was by far the largest
282 (n=2798), reporting on the one-year results of a high risk group scoring 15 or more on the

283 FINDRISC diabetes screening tool who underwent a lifestyle program in primary care (n=400
284 practices). Interventions varied widely, depending on local circumstances, but were broadly
285 based on the Diabetes Prevention Study (DPS) and included both group and individual
286 appointments based on individualized behavioural counseling principles [25]. Average weight
287 loss was modest (1.4% in males, 1.3% in females), but the 17.5% who lost 5% or more of body
288 weight had a relative risk (RR) of 0.31 (95% CI, 0.16 to 0.59) of developing diabetes compared
289 to those whose weight was stable. The interventions included emphasis on both diet and
290 increased physical activity.

291 Studies by Sakane et al. [26] and Penn et al. [27] were much smaller RCTs. Sakane et al.
292 [26] in Japan compared usual care to additional support of 4 group classes over 6 months, with
293 biennial follow-up among people with impaired glucose tolerance (IGT) (n=254). Three-year
294 results were nearly statistically significant even with the small sample size. Mean initial BMI
295 was 24.8; much lower than other studies, in line with the differing diabetes risk profile of East
296 Asians compared to Europeans. The study by Penn et al. [27] was a local site for the European
297 Diabetes Prevention Study (EDIPS), which extended the DPS to different European populations
298 with IGT. The sample size was limited (n=102) and subjects were followed quarterly for up to 5
299 years. A variety of approaches were used, primarily one-on-one counselling with discounts to
300 local gym facilities. While not statistically significant, relative risk (RR) reduction was very
301 similar to the DPS.

302 Two studies looked at reversion of MetS or prediabetes. Bo et al. [19] stands out as one
303 of four methodologically strong studies in the entire review as assessed by the quality assessment
304 tool. Conducted in Italy, they offered four group sessions in addition to medical management for
305 MetS in middle-aged adults (45 to 64 years). Other providers, including medical specialists and

306 nutritionists, were involved. The odds ratio (OR) for having MetS at one year was 0.28 (95% CI,
307 0.18 to 0.44) in the intervention group. Mean weight loss in the intervention group was only 1%,
308 but because of weight gain in the control group receiving usual care (from mean 81.3 kg to 82.9
309 kg), net change in weight was 3%.

310 Finally, Moore et al.[28] in Australia conducted a six-month wait-list trial on a group
311 screened for risk factors of diabetes (IGT or impaired fasting glucose). There were 307
312 participants; 62% of the group identified as having prediabetes and by 6 months, 43% of the
313 intervention group had reverted to normoglycemia compared with 26% of controls. The program
314 has been manualized and consisted of six group sessions and individual follow-up, covering
315 much of the same ground as the DPP.

316 Among the remaining four studies, three assessed different adaptations of the DPP; one in
317 Germany [29] and the other two reports from the same group who developed the original DPP
318 program [30,31]. These diverse studies, conducted in different countries, all included
319 behavioural strategies to improve diet and physical activity, and achieved relatively consistent
320 results. A range of interventions were used, most of which included group classes and
321 intensified follow-up. Mean weight changes were very modest.

322

323 **Diabetes**

324 Of the 128 studies of type 2 diabetes, only 24 (19%) were judged as somewhat or very
325 likely representative of PC patients and had reported clinically relevant changes, predominantly
326 in glycated hemoglobin (A1C). Only Griffin et al [17] assessed CVD incidence. Sixteen of 24
327 studies were conducted with subjects with high baseline A1C levels, and eight among subjects
328 with lower baseline levels. Of these 24 studies, 12 had also recorded weight change and five had

329 achieved clinically relevant weight change of 3% or more, as shown in Additional file 3.

330 **Baseline A1C \geq 9**

331 Of the four RCTs, three (Rothman et al [32], Scott et al [33], Taylor et al[34]) assessed
332 body weight, all were 9-12 months long and focused on overall medical management. Metabolic
333 control was improved, with stable or slightly increased body weight.

334 Among the 12 remaining studies (controlled clinical trials, one group cohort database
335 review) in poorly controlled diabetes that achieved reductions in A1C, two of five studies where
336 weight was measured, achieved relevant weight loss. The Mayer-Davis et al. [35] three-group
337 study results were of interest as weight loss was a focus of this 12-month clinical trial of
338 medically underserved patients with long-standing diabetes in South Carolina. The intensive
339 lifestyle program was based on the DPP, adapted to the local context. The “reimbursement”
340 group received less intensive intervention in line with Medicaid funding and the control group
341 received usual care. A1C improved in all three groups but could not be attributed to the weight
342 loss intervention, as a chronic disease management program was also instituted over the same
343 period of time. Net weight loss of 0.8 BMI units was achieved among those in the intensive
344 program. A team with a Registered Dietitian (RD), specific training and both one-on-one
345 counselling and groups were used. Only Boyd et al. [36] also achieved relevant clinical weight
346 changes in the same range in a very small sample (n=48) of low-income patients. Researchers
347 had partnered with a local YMCA, but only 48 of 130 eligible patients (37%) visited the YMCA
348 on at least one occasion. The results highlight benefits in the minority who will undertake
349 change, as well as challenges with uptake of exercise interventions in some groups.

350 Certainly, some patients achieved modest weight loss, but until additional studies show
351 otherwise, the most realistic weight goal for most patients with higher baseline A1c is weight

352 stabilization.

353

354 **Baseline Hemoglobin A1C < 9**

355 Of the eight remaining studies, the RCT by Griffin et al. [17] was part of the ADDITION
356 trial of intensive medical and lifestyle management of screen-detected type 2 diabetes. As
357 previously noted, CVD incidence was reported but non-significant (intervention: 13.5 per 1000
358 person-years vs. control: 15.9 per 1000 person-years). Overall weight loss in the intervention
359 group was 2% and net weight loss by both groups was similar. The intervention varied in
360 different settings, but consisted of specialized training of providers, a team approach and both
361 one-on-one and group education.

362 Among the seven other studies, Davies et al. [20] was the only cluster RCT (DESMOND)
363 and the third of four studies among the 156 to be considered methodologically strong. This UK
364 group compared a group education program to “additional resources” control in 207 general
365 practices at 13 PC sites. Newly diagnosed patients were referred to the program, while
366 comparator control practices received additional funding to provide equivalent additional contact
367 time with patients and used resources as they saw fit. Many control practices offered group
368 sessions. Registered healthcare professionals received formal training to deliver the program and
369 were supported by a quality assurance component of internal and external assessment to ensure
370 consistency. The group program was six hours long, facilitated by two educators and was
371 focused on lifestyle and self-management. After 12 months, both control and intervention
372 groups decreased their A1C and other clinical outcomes significantly, and to a similar degree,
373 except body weight. Intervention group mean A1C decreased from 8.3 to 6.8 % while control
374 group mean decreased from 7.9 to 6.7 %. Mean body weight decreased by 3.0 kg in the
375 intervention group and 1.9 kg in the control group. Considering the already high caliber of usual

376 diabetes care in the UK, where 59% of diabetics achieve A1C of less than 7.4%, it was argued
377 that it may have been more difficult to show additional benefits of the structured program. The
378 study is particularly noteworthy, as patients and providers were broadly representative, and both
379 arms of the study achieved notable and clinically relevant changes. An additional qualitative
380 study noted both benefits and challenges of group sessions and a range of orientations to self-
381 management among patients, confirming the need for multiple delivery methods [37].

382 As in the study by Griffin et al. [17], screen-detected type 2 diabetes patients were the
383 focus of the study by Janssen et al. [38], another sub-study of the ADDITION trial. Participating
384 PC practices in the Netherlands (n=79) were randomized to usual care versus nurse-led intensive
385 care to manage CVD risk factors. Nurses received additional training on promoting lifestyle and
386 were authorized to adjust medication. Five visits were held in the first 12 weeks, followed by
387 quarterly follow-up visits with the nurse and physician. Mean A1C levels declined in both
388 control (7.4 to 6.5) and intensive groups (7.3 to 6.2) ($p<0.03$), as did other clinical markers. In
389 addition, net change in BMI between intervention and control groups was 1.6 units.

390 Athyros et al. [39] instituted specific training of physicians in Greece with enhanced use
391 of CVD risk calculation, lifestyle counselling and medication management in a mixed group of
392 diabetes patients (n=578), some of whom already had clinical CVD. All clinical indicators
393 improved markedly, including body weight, but the study was judged to be weak and the
394 generalizability of the results was uncertain.

395 These diverse studies provide insight on key aspects to consider. Practice context
396 appears to be critical. In Greece, significant improvement could be achieved by physician
397 training alone, but team practice was already well established in the UK and the Netherlands at
398 baseline. Patient characteristics may have also differed; a number of patients in Greece already

399 had CVD, while newly diagnosed or screen-detected diabetes patients may have been able to
400 lose weight more readily than other groups reviewed. These studies used various combinations
401 of additional providers, incentives, practice guidelines, new delivery methods and chronic
402 disease management strategies; and achieved similar degrees of weight change.

403

404 **Mixed Cardiovascular Disease Risk Studies**

405 Of the 44 studies of subjects with diverse combinations of CVD risk factors or clinical
406 disease, 12 RCTs, one controlled clinical trial, and one cohort study reported at least one
407 clinically relevant change in LDL cholesterol, blood pressure or body weight (Additional file 4).

408 Delaney et al. [18] reported on the 10-year mortality outcomes of an early RCT of nurse-
409 led medication and lifestyle management clinics with patients who had a clinical diagnosis of
410 coronary heart disease in northern Scotland. No data on body weight or clinical markers were
411 published. At 10 years, CVD events (myocardial infarction or CVD death) and total mortality
412 were the same in intervention and control groups.

413 Four studies achieved clinically relevant weight changes (3 kg weight loss or 1 BMI unit
414 decrease) as shown in Additional file 4. Appel et al.'s [40] group reported positive results of a
415 health coaching intervention run outside of PC direct care, but PC physicians got reports on
416 progress. Subjects had at least one CVD risk factor and access to a computer. Two treatment
417 groups received intensive support for weight loss from health coaches; one got remote support
418 (call centre) only, while the other group got remote support plus in-person groups and both were
419 compared to a control group, who got a self-directed manual. Net weight loss between groups
420 (intervention minus control) after 24 months was 1.3 BMI units (or about 4% of body weight).

421 In one of the few studies from Canada, Petrella et al. [41] conducted a randomized trial of
422 a physical activity prescription for 284 older patients from 4 clinics (16 physicians). The

423 intervention consisted of exercise counselling and a physician-administered Step test and
424 prescription of an exercise training target heart rate at baseline, 3 and 6 months. Patients were
425 taught how to assess heart rate. Both exercise and control groups were given a list of available
426 recreation facilities for physical activity participation in their community. BMI decreased by 2.1
427 BMI units in the intervention group and by 0.6 units in the control group. Tracking of physician
428 time indicated counselling took an average of 12 minutes in the intervention group and 7 minutes
429 in the control group. Such tracking provides important information on the intensity and
430 feasibility of the intervention. Older people (> 65 years) capable of exercise were recruited. It is
431 unclear to what degree the results might be generalizable as the sample was recruited
432 opportunistically.

433 In Denmark, Willaing et al. [42] compared referral to a RD with physician counselling in
434 a cluster RCT (n=503). About 68% completed one-year follow-up. Among completers, weight
435 loss was achieved in both groups; RD counselling resulted in mean loss of 4.5 kg (1.1 BMI unit)
436 versus 2.4 kg in the physician only group, but physicians were more likely to actively treat CVD
437 risk factors with medication. Interventions were both conventional one-on-one counselling.

438 Finally, the one group cohort chart audit study by McTigue et al. [43] implementing the
439 12-week group-based DPP curriculum plus additional classes in one clinical centre provides
440 some practical sense of expected success. Of 155 people referred to the program, 72 (43%)
441 enrolled for the costed program. Weight loss averaged 5 kg, compared to weight gain of 0.2 kg
442 among those who were referred but did not enroll. Weight loss was quite consistent at 1-2 BMI
443 units across these diverse studies, which were all at least 12 months long.

444

445 **Health Promotion/Weight Loss**

446 Thirty-six primarily weight control and health promotion studies were identified, but only
447 six (one RCT and five one group cohorts) met our criteria and are summarized in Additional file
448 5. The largest study was the Counterweight program, which began in 2000 in Scotland [44].
449 This study included 75% of subjects with co-morbidities, but the main focus was weight loss.
450 Always conceived as a pre-post implementation study, the 2008 publication provided data on the
451 12- and 24-month outcomes. Program features included 6 months of training and mentoring of
452 practice nurses and feedback to practices on program outcomes. The program was incorporated
453 into 56 practices without additional funding. The intervention included six individual
454 appointments (10–30 minutes each) or six group sessions (1 hour each) over a 3-month period,
455 and then follow-up at 6, 9, 12, 24 months. The sample was large, with 1419 enrolled and
456 involved for at least 12 months. Only 642 (55%) patients provided 12-month data. Mean change
457 in BMI at 12 months among attendees was -1.1 units, with 31% maintaining $\geq 5\%$ weight loss.
458 This amounts to a mean weight loss of -3.0 kg. A 2012 update of wider implementation
459 reported similar results [45].

460 As previously mentioned, the Iori et al. [21] group in Italy recruited a large number of
461 practices ($n=228$) where physicians submitted 10 patients each and 6-month changes were
462 reviewed. Among returnees, weight declined by 5% or more. The generalizability of the study
463 is unclear in spite of the large sample size, as every practice has some patients who can achieve
464 good results with lifestyle change.

465 Among the four remaining small studies Chang et al. [46] conducted an RCT among low
466 income women involved in the Women's, Infants and Children (WIC) program in the US. This
467 study was reviewed as the WIC program provides many primary health care services pre- and
468 post-partum. Control group women lost weight, while intervention women gained weight.

469 Among these studies, the Counterweight program provides the most relevant information
470 for planning purposes [44]. A variety of teaching materials, training and mentoring approaches
471 were used to better support practice nurses to deliver the program.

472

473 **Hypertension, Dyslipidemia and Other Studies**

474 Tables for hypertension, dyslipidemia, complex chronic diseases, pediatrics and
475 pregnancy are shown in Additional files 6-10. The number of studies recording body weight
476 were small. No new promising strategies emerged from the review of these studies.

477

478 **Discussion**

479 Weight management in the PC context is typically only one of many competing priorities,
480 as providers and patients work to provide medical care and support self-management for best
481 health. Self-management training and support is already integral to most programs in diabetes
482 and cardiovascular disease treatment, but may be less common in other areas. Excessive body
483 weight can be conceptualized as a chronic and often progressive condition [4], and similar
484 management principles may be helpful. Weight management could entail a range of goals,
485 including weight loss, weight gain prevention, promotion of physical activity and improved
486 mental health. The focus of this and many other reviews has been body weight change, but the
487 results of the diabetes incidence studies suggest that other unmeasured factors may be more
488 important, since mean weight change was so modest in those studies. Since disease incidence
489 studies are very expensive, additional work is needed to identify more valid intermediate markers
490 for health risk, that can be used in future implementation studies to assess and improve the
491 effectiveness of such lifestyle programs. Different groups of providers could offer interventions

492 and formats or channels could differ.

493 To identify promising approaches, this systematic scoping review was undertaken to
494 focus on the most promising studies to date, in the context of typical PC. Most studies were
495 focused on diabetes and mixed CVD risk management. While the most promising studies with a
496 lifestyle focus did achieve modest weight losses in the range of previous systematic reviews (3kg
497 or 3% or 1 BMI unit) [10], narrative analysis of key features of the interventions did not reveal
498 any one key intervention, partly because of the complexity of assessing relevant contextual and
499 patient factors. Better and in common methods of describing such factors is needed.

500 The most promising approaches had multiple elements including clear processes for
501 diagnosis and assessment, training of providers, enhanced scope of practice, quality control,
502 sustained programming and follow-up, and were broadly based on principles for sustained health
503 behaviour change. Additional studies, especially in prediabetes and metabolic syndrome where
504 reduction in diabetes incidence has been shown, are needed to determine what combinations of
505 strategies will be most effective in different PC systems.

506 Based on previous work by us and others [44,47,48], it was known from the outset that
507 diabetes and CVD would be prominent conditions in PC, and that approximately 50% of people
508 undertaking lifestyle change in PC drop-out of lifestyle change programs. Study subjects in all
509 types of medical management studies tend not to be representative of all patients, but the
510 problem is particularly challenging in behavioural interventions where active involvement of
511 participants is key to successful results. In addition, there may be substantial differences in
512 response to interventions by socio-demographic and other factors. For example, most specialist
513 studies have been conducted mainly in women, yet substantial proportions of men are also
514 overweight and obese and suffer from the attendant conditions. Therefore, we decided to review

515 only studies conducted in PC settings, in hopes that the subjects would be more representative as
516 evaluated by the quality assessment tool, and the interventions more relevant to the PC context.

517 This issue of indirectness, or the extent to which the groups under study are
518 representative of the population of interest, has been addressed by systematic review
519 methodologists using the GRADE system, by making a consensus judgment. It has recently
520 been noted that such judgments may be unreliable [49]. Further methodological work is needed
521 to adequately address this issue. It is uncertain at this point whether choosing only studies in the
522 setting of interest is an advance.

523 Operationalizing study selection for the PC setting proved to be somewhat difficult in
524 practice, since “setting” is not a typical keyword for cataloguing and searching purposes.
525 Review of study methods was necessary to select studies. Studies based on newspaper or
526 community advertisement, conducted by specialist providers or centres could be excluded at
527 study selection, but studies that were not clear on recruitment were more problematic. A second
528 step was therefore taken in excluding studies at quality assessment that were deemed as either
529 “not representative” or “can’t tell” by reviewers. In all cases, two reviewers agreed on selection.
530 In spite of these efforts, we expect that our selection of studies may or may not be supported by
531 other reviewers. We have therefore supplied the lists of both included and excluded studies (see
532 Additional file 11).

533 Most systematic reviews privilege RCTs, often excluding pre-post studies, a common
534 and feasible study design in implementation research. It is generally accepted that internal
535 validity is a primary concern in establishing efficacy, but this approach may be too limiting in
536 considering generalizability, especially if the researchers have taken steps to avoid many of the
537 common sources of bias. We therefore did not exclude on this criterion at the start of the review,

538 and instead considered all studies, but separated out studies by study design, recognizing the
539 potential for bias and confounding in non-randomized contexts. Notably, some important
540 studies, including the FIN-D2D [24] and Counterweight studies [44,45], were retained and
541 offered excellent insight to the possible success of weight management programs in specific PC
542 practice.

543 The severity of the patients' clinical conditions and medical management itself (including
544 side-effects of medications), can be expected to affect outcomes of weight management in the
545 context of overall medical management. We therefore attempted to categorize studies broadly by
546 disease and secondly by severity. This was most obvious in the diabetes studies, where the focus
547 of care for poorly controlled diabetes would necessarily be focused on control of blood glucose
548 and blood pressure rather than weight, and where addition of medications would tend to increase
549 body weight. One strength of this review was the focus on weight management in the context of
550 the many chronic conditions routinely treated in PC.

551 Even with these efforts to compare studies within broad groupings, studies were very
552 diverse, so that only broad conclusions are possible. Among all the studies, the reports of Davies
553 et al. [20] in newly diagnosed diabetes in the UK (both control and intervention groups), Janssen
554 et al. [38] in screen-detected diabetes in the Netherlands, and the Counterweight Program in the
555 UK [50] achieved clinically relevant weight control in sizable samples. All three studies were
556 large well-organized studies (two trials and one pre-post study) that used a comprehensive suite
557 of intervention strategies. Other studies, such as Greaves et al. [51] and Moore et al. [52], also
558 employed additional providers and multiple approaches, yet intervention subjects achieved less
559 weight loss than control subjects. If there were flaws in these latter studies, they were not
560 obvious in review. The results, however, remind us that additional work is required to describe

561 context and patients better, as well as determine which KEY aspects need to be included in any
562 future implementation studies.

563 The most promising results were achieved in prediabetes or screen-detected diabetes. We
564 have insufficient information to determine if clinically relevant modest weight loss is possible in
565 the majority of patients with poorly controlled diabetes, CVD risk factors, or chronic diseases.
566 Between 10 and 20% of patients were able to achieve relevant weight loss (3%) in some studies.
567 The Counterweight program achieved weight loss of $\geq 5\%$ in only 13% of all enrolled subjects
568 [44], while in the FIN D2D assessment 17.5% achieved such weight loss [24]. This latter finding
569 is relevant, as it confirms previous findings that weight loss of this magnitude will be achieved
570 by a minority of subjects.

571 Missing from the literature were any studies on weight gain prevention in otherwise
572 healthy or overweight children and adults in PC. Few of the studies focused on this topic, but the
573 study of Bo et al. [19], a strong study of patients with MetS, was suggestive, in that the control
574 group gained substantial weight. Additional studies in this high-risk target group are needed.

575

576 **Limitations**

577 Like self-care services in chronic diseases, obesity management in PC is a difficult area to
578 tackle successfully, balancing additional services with their associated costs to achieve improved
579 health for the majority of patients. The major limitation of this and other literature reviews is
580 that the evidence base for formulating new services is relatively weak, with major gaps in our
581 knowledge. From this review it is clear that we need a better understanding of which key
582 components must be included in obesity management programs in PC, and how to ensure that
583 costly, ineffective services are avoided.

584 A modified review methodology was used. It drew from established systematic literature
585 review methods on quality and outcome assessment. Our choice to limit by pre-defined clinical
586 change criteria is only one approach, which required substantial work to first determine the
587 degree of expected change and then to tabulate across studies. Limiting the review to include
588 only RCTs would have substantially shortened the process, but a few important studies would
589 have been missed. In fact, most promising interventions we found were also methodologically
590 strong studies. There is a need to further develop review methods for implementation studies.
591 There were significant challenges in identifying studies located in PC, and a wide variety of
592 outcomes were assessed. A move to larger cluster randomized trials, with broad consensus on
593 key outcomes and methods of assessment would improve the evidence base.

594

595 **Conclusions**

596 Given the underlying difficulty of obesity management [34], we attempted to assess
597 whether the PC literature would yield new insights on promising interventions. A few studies
598 using intensive approaches were able to achieve weight losses in the range of those seen in
599 previous systematic reviews. The tactic of including all study designs and focusing on those
600 studies able to show relevant changes, suggested that comprehensive programs have the best
601 chance of success. The most promising studies intensified interventions through a combination
602 of increased physician efforts along with additional providers, well established protocols for
603 management, and a range of additional resources, mentoring and performance monitoring. The
604 review approach was helpful in identifying a few promising studies, which can provide the basis
605 for new intervention studies. It is premature to implement broad programs for obesity
606 management in PC until more cluster randomized trials are completed.

607 **List of Abbreviations:**

608 A1C = glycated hemoglobin

609 BMI = body mass index

610 BP = blood pressure

611 CVD = cardiovascular disease

612 DM = diabetes

613 DPP = Diabetes Prevention Program

614 DPS = Diabetes Prevention Study

615 IFG = impaired fasting glucose

616 IGT = impaired glucose tolerance

617 MD = physician

618 MetS = cardiometabolic syndrome

619 NP = nurse practitioner

620 PC = primary care

621 RCT = randomized controlled trial

622 RN = registered nurse

623 RR = relative risk

624 USPSTF = United States Preventive Services Task Force

625

626 **Declaration of interest:** The authors declare they have no competing interests.

627

628 **Author's contributions:**

629 OO was involved in the conception of the review, the acquisition, analysis and interpretation of
630 the data, and drafted the manuscript.

631 PB was involved in the conception of the review, the acquisition, analysis and interpretation of
632 the data, and drafted the manuscript.

633 DR was involved in the acquisition, analysis and interpretation of data, and drafted the
634 manuscript.

635 LB was involved in the analysis and interpretation of data.
636 JJM was involved in the conception of the review and the interpretation of data.
637 AME was involved in the analysis and interpretation of data.
638 TH was involved in the interpretation of data.
639 NK was involved in the conception of the study and the interpretation of data.
640 HS was involved in the interpretation of data.
641 RK was involved in the interpretation of data.
642 All authors have reviewed the manuscript and given approval for publication.
643

644 **Acknowledgments:** Thanks to the Advsiory Committee for the overall project:
645 o Linda Dietrich, Dietitians of Canada, Toronto, ON
646 o Diana Lawlor, Nova Scotia Health, Halifax, NS
647 o Kay Watson-Jarvis, Calgary, AB
648 o Ruth Wilson, College of Family Physicians of Canada, Family Medicine, Kingston, ON
649 Thanks to the student research assistants: Edwobah Ackah, Elizabeth Lee, Alissa Lunney, Laura
650 Montgomery, Tracy Ng, Amanda Paashuis
651

652 **Funding:** CIHR Knowledge to Action, 200805KAL-189174-KAL-CEHA-55685 and Meetings,
653 Planning and Dissemination, KT Supplement 21010KTB-238517-KTB-CEHA55685. Funding
654 from the Ontario government Work-Study program supplemented the wages of some student
655 research assistants. A portion of the review was completed as the Master’s thesis project of
656 Olivia O’Young.
657

658 **References**

- 659 1. Jensen MD, Ryan DH, Donato KA, Apovian CM, Ard JD, Comuzzie AG, Donato KA,
660 Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-
661 Sunyer X, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ: **Executive**
662 **summary: Guidelines (2013) for the management of overweight and obesity in**
663 **adults..a report of the American College of Cardiology/American Heart Association**
664 **Task Force on Practice Guidelines and the Obesity Society published by**
665 **the Obesity Society and American College of Cardiology/American Heart**
666 **Association Task Force on Practice Guidelines. Based on a systematic review from**
667 **the The Obesity Expert Panel, 2013. *Obesity* 2014, 22:S5-S39**
- 668 2. Moyer VA, US Preventive Services Task Force: **Screening for and management of**
669 **obesity in adults: U.S. Preventive Services Task Force recommendation statement.**
670 *Ann Intern Med* 2012, **157**:373-378.
- 671 3. Australian Primary Care Research Institute. The Centre for Obesity Management and
672 Prevention Research Excellence in Primary Health Care. Australia: Australian Primary
673 Care Research Institute; 2012.
- 674
- 675 4. Sharma AM, Padwal R: **Obesity is a sign - over-eating is a symptom: an aetiological**
676 **framework for the assessment and management of obesity. *Obes Rev* 2010, 11:362-**
677 **370.**
- 678 5. Riediger ND, Clara I: **Prevalence of metabolic syndrome in the Canadian adult**
679 **population. *CMAJ* 2011, 183:E1127-E1134.**
- 680 6. Cardiometabolic Risk Working Group Executive Committee, Leiter LA, Fitchett DH,
681 Gilbert RE, Gupta M, Mancini GB, McFarlane PA, Ross R, Teoh H, Verma S, Anand S,
682 Camelon K, Chow CM, Cox JL, Despres JP, Genest J, Harris SB, Lau DC, Lewanczuk R,
683 Liu PP, Lonn EM, McPherson R, Poirier P, Qaadri S, Rabasa-Lhoret R, Rabkin SW,
684 Sharma AM, Steele AW, Stone JA, Tardif JC, Tobe S, *et al.*: **Cardiometabolic risk in**
685 **Canada: a detailed analysis and position paper by the cardiometabolic risk working**
686 **group. *Can J Cardiol* 2011, 27:e1-e33.**
- 687 7. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA,
688 Nathan DM; Diabetes Prevention Program Research Group: **Reduction in the incidence**
689 **of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002,**
690 **346:393-403.**
- 691 8. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF,
692 Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E,
693 Nathan DM: **10-year follow-up of diabetes incidence and weight loss in the Diabetes**
694 **Prevention Program Outcomes Study. *Lancet* 2009, 374:1677-1686.**
- 695 9. Carvajal R, Wadden TA, Tsai AG, Peck K, Moran CH: **Managing obesity in primary**

- 696 **care practice: a narrative review.** *Ann N Y Acad Sci* 2013, **1281**:191-206.
- 697 10. Leblanc ES, O'Connor E, Whitlock EP, Patnode CD, Kapka T: **Effectiveness of primary**
698 **care-relevant treatments for obesity in adults: a systematic evidence review for the**
699 **U.S. Preventive Services Task Force.** *Ann Intern Med* 2011, **155**:434-447.
- 700 11. Peirson L, Douketis J, Ciliska D, Fitzpatrick-Lewis D, Usman A, Raina P. **Treatment of**
701 **overweight / obesity in adult populations: A systematic review and meta-analyses**
702 **conducted for the Canadian Task Force on Preventive Health Care.** *CMAJ Open*, in
703 press..
- 704 12. Gough D, Thomas J, Oliver S: **Clarifying differences between review designs and**
705 **methods.** *Syst Rev* 2012, **1**:28.
- 706 13. Arksey H, O'Malley L: **Scoping studies: towards a methodological framework.** *Int J*
707 *Soc Res Methodol* 2005, **8**:1-14.
- 708 14. Shepperd S, Lewin S, Straus S, Clarke M, Eccles MP, Fitzpatrick R, Wong G, Sheikh A:
709 **Can we systematically review studies that evaluate complex interventions?** *PLoS*
710 *Med* 2009, **6**:e1000086.
- 711 15. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated
712 September 2009]. Edited by Higgins JPT, Grren S. Cochrane Collaboration; 2009.
- 713 16. Ciliska D, Thomas H, Catallo C, Gauld M, Kingston D, Cantwell B, Freeborn C, Stevens
714 R, Gesgjorskyj T, Jahn P: The effectiveness of nutrition interventions for prevention and
715 treatment of chronic disease in primary care settings: a systematic literature review.
716 Toronto: Dietitians of Canada; 2006.
- 717 17. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GEHM, Sandbaek A, Sharp
718 SJ, Simmons RK, van den Donk M, Wareham NJ, Lauritzen T: **Effect of early intensive**
719 **multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2**
720 **diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial.**
721 *Lancet* 2011, **378**:156-167.
- 722 18. Delaney EK, Murchie P, Lee AJ, Ritchie LD, Campbell NC: **Secondary prevention**
723 **clinics for coronary heart disease: a 10-year follow-up of a randomised controlled**
724 **trial in primary care.** *Heart* 2008, **94**:1419-1423.
- 725 19. Bo S, Ciccone G, Baldi C, Benini L, Dusio F, Forastiere G, Lucia C, Nuti C, Durazzo M,
726 Cassader M, Gentile L, Pagano G: **Effectiveness of a lifestyle intervention on**
727 **metabolic syndrome. A randomized controlled trial.** *J Gen Intern Med* 2007, **22**:1695-
728 1703.
- 729 20. Davies MJ, Heller S, Skinner TC, Campbell MJ, Carey ME, Craddock S, Dallosso HM,
730 Daly H, Doherty Y, Eaton S, Fox C, Oliver L, Rantell K, Rayman G, Khunti K; Diabetes
731 Education and Self Management for Ongoing and Newly Diagnosed Collaborative:
732 733

- 734 **Effectiveness of the diabetes education and self management for ongoing and newly**
735 **diagnosed (DESMOND) programme for people with newly diagnosed type 2**
736 **diabetes: cluster randomised controlled trial. *BMJ* 2008, 336:491-495.**
- 737 21. Iori I, Fatati G, Fusco MA, Leonardi F, Matthieu G, Scanelli G, Lanti M, Menotti A:
738 **Survey of Cardiovascular Risk Factors in Overweight and Obese Patients (SCOOP**
739 **Study) Six-month changes in risk factor levels and cardiovascular risk. *Eur J Int Med***
740 **2009, 20:280-288.**
- 741 22. Johnston BC, Kanters S, Bandayrel K: **Comparison of weight loss among named diet**
742 **programs in overweight and obese adults: A meta-analysis. *JAMA* 2014, 312: 923-**
743 **933.**
- 744 23. Lin JS, O'Connor E, Evans CV, Senger CA, Rowland MG, Groom HC: **Behavioral**
745 **counseling to promote a healthy lifestyle in persons with cardiovascular risk factors:**
746 **a systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med***
747 **2014, Aug 26 [Epub ahead of print].**
- 748 24. Saaristo T, Moilanen L, Korpi-Hyovalti E, Vanhala M, Saltevo J, Niskanen L, Jokelainen
749 J, Peltonen M, Oksa H, Tuomilehto J, Uusitupa M, Keinänen-Klukaanniemi S: **Lifestyle**
750 **intervention for prevention of type 2 diabetes in primary health care: one-year**
751 **follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D). *Diabetes***
752 **Care 2010, 33:2146-2151.**
- 753 25. Lindstrom J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, Uusitupa M,
754 Tuomilehto J; Finnish Diabetes Prevention Study Group: **The Finnish Diabetes**
755 **Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and**
756 **physical activity. *Diabetes Care* 2003, 26:3230-3236.**
- 757 26. Sakane N, Sato J, Tsushita K, Tsujii S, Kotani K, Tsuzaki K, Tominaga M, Kawazu S,
758 Sato Y, Usui T, Kamae I, Yoshida T, Kiyohara Y, Sato S, Kuzuya H; Japan Diabetes
759 Prevention Program (JDPP) Research Group: **Prevention of type 2 diabetes in a**
760 **primary healthcare setting: Three-year results of lifestyle intervention in Japanese**
761 **subjects with impaired glucose tolerance. *BMC Public Health* 2011, 11:40.**
- 762 27. Penn L, White M, Oldroyd J, Walker M, Alberti KGMM, Mathers JC: **Prevention of**
763 **type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes**
764 **Prevention RCT in Newcastle upon Tyne, UK. *BMC Public Health* 2009, 9:342.**
- 765 28. Moore SM, Hardie EA, Hackworth NJ, Critchley CR, Kyrios M, Buzwell SA, Crafti
766 NA.: **Can the onset of type 2 diabetes be delayed by a group-based lifestyle**
767 **intervention? A randomised control trial. *Psychol Health* 2011, 26:485-499.**
- 768 29. Kulzer B, Hermanns N, Gorges D, Schwarz P, Haak T: **Prevention of diabetes self-**
769 **management program (PREDIAS): effects on weight, metabolic risk factors, and**
770 **behavioral outcomes. *Diabetes Care* 2009, 32:1143-1146.**
- 771 30. Kramer MK, McWilliams JR, Chen HY, Siminerio LM: **A community-based Diabetes**

- 772 **prevention program evaluation of the group lifestyle balance program delivered by**
773 **diabetes educators.** *Diabetes Educator* 2011, **37**:659-668.
- 774 31. Kramer MK, Kriska AM, Venditti EM, Miller RG, Brooks MM, Burke LE, Siminerio
775 LM, Solano FX, Orchard TJ: **Translating the Diabetes Prevention Program: a**
776 **comprehensive model for prevention training and program delivery.** *Am J Prev Med*
777 2009, **37**:505-511.
- 778 32. Rothman RL, Malone R, Bryant B, Shintani AK, Crigler B, DeWalt DA, Dittus RS,
779 Weinberger M, Pignone MP: **A randomized trial of a primary care-based disease**
780 **management program to improve cardiovascular risk factors and glycated**
781 **hemoglobin levels in patients with diabetes.** *Am J Med* 2005, **118**:276-284.
- 782 33. Scott DM, Boyd ST, Stephan M, Augustine SC, Reardon TP: **Outcomes of pharmacist-**
783 **managed diabetes care services in a community health center.** *Am J Health Syst*
784 *Pharm* 2006, **63**:2116-2122.
- 785 34. Taylor CB, Miller NH, Reilly KR, Greenwald G, Cunning D, Deeter A , Abascal L:
786 **Evaluation of a nurse-care management system to improve outcomes in patients**
787 **with complicated diabetes.** *Diabetes Care* 2003, **26**:1058-1063.
- 788 35. Mayer-Davis EJ, D'Antonio AM, Smith SM, Kirkner G, Levin MS, Parra-Medina D,
789 Schultz R: **Pounds off with empowerment (POWER): a clinical trial of weight**
790 **management strategies for black and white adults with diabetes who live in**
791 **medically underserved rural communities.** *Am J Public Health* 2004, **94**:1736-1742.
- 792 36. Boyd ST, Scott DM, Augustine SC: **Exercise for low-income patients with diabetes: a**
793 **continuous quality improvement project.** *Diabetes Educ* 2006, **32**:385-393.
- 794 37. Ockleford E, Shaw RL, Willars J, Dixon WM: **Education and self-management for**
795 **people newly diagnosed with type 2 diabetes: a qualitative study of patients' views.**
796 *Chronic Illn* 2008, **4**:28-37.
- 797 38. Janssen PG, Gorter KJ, Stolk RP, Rutten GE: **Randomised controlled trial of intensive**
798 **multifactorial treatment for cardiovascular risk in patients with screen-detected**
799 **type 2 diabetes: 1-year data from the ADDITION Netherlands study.** *Br J Gen Pract*
800 2009, **59**:43-48.
- 801 39. Athyros VG, Hatzitolios A, Karagiannis A, Didangelos TP, Iliadis F, Dolgyras S,
802 Vosnakidis T, Vasiliadis P, Malias I, Tziomalos K, Samouilidou M, Mikhalidis DP;
803 INDEED Collaborative Group.: **Initiative for a new diabetes therapeutic approach in**
804 **a Mediterranean country: the INDEED study.** *Curr Med Res Opin* 2009, **25**:1931-
805 1940.
- 806 40. Appel LJ, Clark JM, Yeh HC, Wang NY, Coughlin JW, Daumit G, Miller ER 3rd, Dalcin
807 A, Jerome GJ, Geller S, Noronha G, Pozefsky T, Charleston J, Reynolds JB, Durkin N,
808 Rubin RR, Louis TA, Brancati FL: **Comparative effectiveness of weight-loss**
809 **interventions in clinical practice.** *N Engl J Med* 2011, **365**:1959-1968.

- 810 41. Petrella RJ, Koval JJ, Cunningham DA, Paterson DH: **Can primary care doctors**
811 **prescribe exercise to improve fitness? The Step Test Exercise Prescription (STEP)**
812 **project.** *Am J Prev Med* 2003, **24**:316-322.
- 813 42. Willaing I, Ladelund S, Jorgensen T, Simonsen T, Nielsen LM: **Nutritional counselling**
814 **in primary health care: a randomized comparison of an intervention by general**
815 **practitioner or dietician.** *Eur J Cardiovasc Prev Rehabil* 2004, **11**:513-520.
- 816 43. McTigue KM, Conroy MB, Bigi L, Murphy C, McNeil M: **Weight loss through living**
817 **well: translating an effective lifestyle intervention into clinical practice.** *Diabetes*
818 *Educ* 2009, **35**:199-204.
- 819 44. Counterweight Project Team: **Evaluation of the Counterweight Programme for**
820 **obesity management in primary care: a starting point for continuous improvement.**
821 *Br J Gen Pract* 2008, **58**:548-554.
- 822 45. Counterweight Project Team: **The implementation of the Counterweight Programme**
823 **in Scotland, UK.** *Fam Pract* 2012, **29 Suppl 1**:i139-i144.
- 824 46. Chang MW, Nitzke S, Brown R: **Design and outcomes of a Mothers In Motion**
825 **behavioral intervention pilot study.** *J Nutr Educ Behav* 2010, **42**:S11-S21.
- 826 47. Brauer P, Toews H, Northmore D, Davidson B, West E, Dietrich L, Schneider T:
827 Effectiveness of Registered Dietitian Counselling: Interdisciplinary Nutrition Services in
828 Family Health Networks Demonstration Project. Report to the Ontario Ministry of Health
829 and Long Term Care; 2006.
830
- 831 48. Crustolo AM, Kates N, Ackerman S, Schamehorn S: **Integrating nutrition services into**
832 **primary care: Experience in Hamilton, Ont.** *Can Fam Physician* 2005, **51**:1647-1653.
- 833 49. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, Moe-Byrne T,
834 Higgins JP, Sowden A, Stewart G: **A checklist designed to aid consistency and**
835 **reproducibility of GRADE assessments: development and pilot validation.** *Syst Rev*
836 2014, **3**:82.
- 837 50. Counterweight Project Team: **Influence of body mass index on prescribing costs and**
838 **potential cost savings of a weight management programme in primary care.** *J Health*
839 *Serv Res Policy* 2008, **13**:158-166.
- 840 51. Greaves CJ, Middlebrooke A, O'Loughlin L, Holland S, Piper J, Steele A, Gale T,
841 Hammerton F, Daly M: **Motivational interviewing for modifying diabetes risk: a**
842 **randomised controlled trial.** *Br J Gen Pract* 2008, **58**:535-540.
- 843 52. Moore H, Summerbell CD, Greenwood DC, Tovey P, Griffiths J, Henderson M, Hesketh
844 K, Woolgar S, Adamson AJ: **Improving management of obesity in primary care:**
845 **cluster randomised trial.** *BMJ* 2003, **327**:1085.

- 846 53. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee:
847 **Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention**
848 **and Management of Diabetes in Canada.** *Can J Diabetes* 2013, **37**:S1-S212.
- 849 54. Cardiometabolic Risk Working Group Executive Committee, Leiter LA, Fitchett DH,
850 Gilbert RE, Gupta M, Mancini GB, McFarlane PA, Ross R, Teoh H, Verma S, Anand S,
851 Camelon K, Chow CM, Cox JL, Despres JP, Genest J, Harris SB, Lau DC, Lewanczuk R,
852 Liu PP, Lonn EM, McPherson R, Poirier P, Qaadri S, Rabasa-Lhoret R, Rabkin SW,
853 Sharma AM, Steele AW, Stone JA, Tardif JC, Tobe S, *et al.*: **Cardiometabolic risk in**
854 **Canada: a detailed analysis and position paper by the cardiometabolic risk working**
855 **group.** *Can J Cardiol* 2011, **27**:e1-e33.
- 856 55. Bihan H, Takbou K, Cohen R, Michault A, Boitou F, Reach G, Le Clésiau H: **Impact of**
857 **short-duration lifestyle intervention in collaboration with general practitioners in**
858 **patients with the metabolic syndrome.** *Diabetes Metab* 2009, **35**:185-191.
- 859 56. Absetz P, Valve R, Oldenburg B, Heinonen H, Nissinen A, Fogelholm M, Ilvesmäki
860 V, Talja M, Uutela A: **Type 2 diabetes prevention in the "real world": one-year**
861 **results of the GOAL Implementation Trial.** *Diabetes Care* 2007, **30**:2465-2470.
- 862 57. Almeida FA, Shetterly S, Smith-Ray RL, Estabrooks PA: **Reach and effectiveness of a**
863 **weight loss intervention in patients with prediabetes in Colorado.** *Prev Chronic Dis*
864 2010, **7**:A103.
- 865 58. Avram C, Iurciuc M, Craciun L, Avram A, Iurciuc S, Oancea C, Gaita D: **Dietary and**
866 **physical activity counseling in high-risk asymptomatic patients with metabolic**
867 **syndrome - A primary care intervention.** *Journal of Food Agriculture & Environment*
868 2011, **9**:16-19.
- 869 59. Boltri JM, Okosun I, Davis-Smith YM, Seale JP, Roman P, Tobin BW: **A simple nurse-**
870 **based prompt increases screening and prevention counseling for diabetes.** *Diabetes*
871 *Res Clin Pract* 2007, **75**:81-87.
- 872 60. Botomino A, Rudolf B, Krahenbuhl S, Hersberger KE: **Change of body weight and**
873 **lifestyle of persons at risk for diabetes after screening and counselling in**
874 **pharmacies.** *Pharm World Sci* 2008, **30**:222-226.
- 875 61. Christian JG, Byers TE, Christian KK, Goldstein MG, Bock BC, Pioreschi B, Bessesen
876 DH: **A computer support program that helps clinicians provide patients with**
877 **metabolic syndrome tailored counseling to promote weight loss.** *J Am Diet Assoc*
878 2011, **111**:75-83.
- 879 62. Kinmonth AL, Wareham NJ, Hardeman W, Sutton S, Prevost AT, Fanshawe T, Williams
880 KM, Ekelund U, Spiegelhalter D, Griffin SJ: **Efficacy of a theory-based behavioural**
881 **intervention to increase physical activity in an at-risk group in primary care**
882 **(ProActive UK): a randomised trial.** *Lancet* 2008, **371**:41-48.
- 883 63. Laatikainen T, Dunbar JA, Chapman A, Kilkkinen A, Vartiainen E, Heistaro S, Philpot

- 884 B, Absetz P, Bunker S, O'Neil A, Reddy P, Best JD, Janus ED: **Prevention of type 2**
885 **diabetes by lifestyle intervention in an Australian primary health care setting:**
886 **Greater green triangle (GGT) diabetes prevention project.** *BMC Public Health* 2007,
887 7:249.
- 888 64. Makrilakis K, Liatis S, Grammatikou S, Perrea D, Katsilambros N: **Implementation and**
889 **effectiveness of the first community lifestyle intervention programme to prevent**
890 **Type 2 diabetes in Greece. The DE-PLAN study.** *Diabe Med* 2010, 27:459-465.
- 891 65. Mensink M, Feskens EJ, Saris WH, De Bruin TW, Blaak EE: **Study on lifestyle**
892 **intervention and impaired glucose tolerance maastricht (SLIM): preliminary results**
893 **after one year.** *Int J Obes Relat Metab Disord* 2003, 27:377-384.
- 894 66. Nilsen V, Bakke PS, Gallefoss F: **Effects of lifestyle intervention in persons at risk for**
895 **type 2 diabetes mellitus - results from a randomised, controlled trial.** *BMC Public*
896 *Health* 2011, 11:893.
- 897 67. Oldroyd JC, Unwin NC, White M, Mathers JC, Alberti KGM: **Randomised controlled**
898 **trial evaluating lifestyle interventions in people with impaired glucose tolerance.**
899 *Diab Res Clin Pract* 2006, 72:117-127.
- 900 68. Smith-Ray RL, Almeida FA, Bajaj J, Foland S, Gilson M, Heikkinen S, Seagle H,
901 Estabrooks PA: **Translating efficacious behavioral principles for diabetes prevention**
902 **into practice.** *Health Promot Pract* 2009, 10:58-66.
- 903 69. Wadden TA, Volger S, Sarwer DB, Vetter ML, Tsai AG, Berkowitz RI *et al.*: **A Two-**
904 **Year Randomized Trial of Obesity Treatment in Primary Care Practice.** *N Engl J*
905 *Med* 2011, 365:1969-1979.
- 906 70. Whittemore R, Melkus G, Wagner J, Dziura J, Northrup V, Grey M: **Translating the**
907 **diabetes prevention program to primary care: a pilot study.** *Nurs Res* 2009, 58:2-12.
- 908 71. Yamashiro T, Nishikawa T, Isami S, Wei CN, Fukumoto K, Matsuo H, Yoshinaga T,
909 Kukidome D, Motoshima H, Matsumura T, Ueda A, Araki E: **The effect of group-based**
910 **lifestyle interventions on risk factors and insulin resistance in subjects at risk for**
911 **metabolic syndrome: the Tabaruzaka Study 1.** *Diabetes Obes Metab* 2010, 12:790-
912 797.
- 913
914
915
916

917

918 **Figure legends**

919

920 Figure 1. Study Selection Process.

921

922 Figure 2. Location of Studies by Country. Other countries (11% or 31 studies): Denmark 3
923 studies; France 3; Greece 3; Ireland 3; Norway 3; Belgium 2; Brazil 2; China 2; Switzerland 2;
924 both Australia and New Zealand 1; Austria 1; Chile 1; Korea 1; Mexico 1; Singapore 1; Taiwan
925 1; Turkey 1.

926 Figure 3. Number of Studies by Disease/Condition Focus (n=280)

927

928
929

Table 1. Clinically Relevant Change Criteria in Intervention Groups

	Mean Change	% Change	Source
Children			
BMI	Z score change varies by height and weight – all studies reviewed		U.S. Preventive Services Task Force (USPSTF) [10]
Adults			
Incidence of disease or mortality	All studies reviewed		
Reversion of Metabolic Syndrome	All studies reviewed		
Weight (kg)	3 kg	3	USPSTF [10]
BMI	1 Unit		
A1C (%)	1.0		Canadian Diabetes Association [53]
LDL-cholesterol		11	Cardiometabolic Risk Working Group [54]
Systolic Blood Pressure (mm Hg)	5	4	Cardiometabolic Risk Working Group [54]
Diastolic Blood Pressure (mm Hg)	4	4	Cardiometabolic Risk Working Group [54]

930

Table 2: At Risk for Diabetes or Metabolic Syndrome Studies Reporting Clinically Relevant Changes¹

Author/Date	Overall QA ²	Focus	Wt / BMI	A1C	Lipids LDL-C	SBP / DBP	Baseline LDL-C	Baseline SBP	Disease incidence	Representative ³
Randomized Controlled Trials										
Bo et al., (2007)[19]	Strong	MetS, lifestyle	xx		x (TC)	x		143	Intervention versus control: MetS prevalence reduction: 70.4% to 34.9% vs. 72.3 to 66%; Odds Ratio for having MetS at end of study = 0.28 (95% CI, 0.18 to 0.44)	vl
Kulzer et al., 2009[29]	Moderate	Prediabetes, Adapted Diabetes Prevention Program [7]	xx	x		xx		142		sw
Moore et al. 2011 [28]	Moderate	Prediabetes; lifestyle counselling	xx		x	xx	2.9	129	Intervention versus control: 13% vs 7% developed DM 43% vs 26% normalized (p<0.01) 45% vs 67% remained pre-DM	sw
Penn et al., 2009 [27]	Weak	Impaired glucose tolerance, Diabetes Prevention Study lifestyle	x						Intervention versus control: Incidence DM 33/1000 person years (py) vs. 67/1000 py RR 0.45 (95% CI, 0.2 to 1.2, NS)	sw
Sakane et al., 2011 [26]	Weak	Impaired glucose tolerance, lifestyle counselling	x						Intervention versus control: DM Incidence 8.2% vs 14.8% over 3 years (NS, p=0.097)	sw
Cohort – One Group										
Bihan et al., (2009)[55]	Weak	MetS; lifestyle			xx (HDL)	xx		142		sw
Kramer et al., (2009) [31]	Weak	High risk for DM; lifestyle Adapted Diabetes	xx				x			sw

Author/Date	Overall QA ²	Focus	Wt / BMI	A1C	Lipids LDL-C	SBP / DBP	Baseline LDL-C	Baseline SBP	Disease incidence	Representative ³
		Prevention Program								
Kramer et al., 2011 [30]	Weak	High risk for DM; lifestyle Adapted Diabetes Prevention Program	xx		x	xx	3.1	128		sw
Saaristo et al. 2010 [24]	Weak	Prediabetes, lifestyle Finish Diabetes Prevention Program (FIN-D2D)	x		x	x			DM incidence: NGT = 1-2% IFG = 7-14% IGT = 11-16% <u>Relative Risk (RR) of DM by weight lost:</u> <u>≥5% weight loss:</u> RR, 0.31 (95% CI, 0.16 to 0.59) <u>2.5-4.9% weight loss:</u> RR, 0.72 (95% CI, 0.46 to 1.13) <u>Gained ≥2.5% weight:</u> RR, 1.10 (95% CI, 0.77 to 1.58)	vl

¹All studies bolded **xx** demonstrated clinically relevant weight loss (≥3% weight loss OR decrease of ≥1 BMI unit), glycated hemoglobin (A1C) (≥1% decrease), LDL-cholesterol (≥11% decrease in LDL-C levels) and blood pressure [BP] (≥4% decrease in systolic [SBP] or diastolic [DBP]).

² QA = quality assessment rating [15].

³ Representative refers to the question: Are the individuals selected to participate likely to be representative of the target population? vl = very likely; sw = somewhat likely

TC = total cholesterol; med mgt= medical management, MetS = metabolic syndrome, DM = diabetes, NGT = normal glucose tolerance, IFG = impaired fasting glucose, IGT = impaired glucose tolerance

Table 3: Providers and Delivery Channels of Prediabetes or Metabolic Syndrome Studies

Author / Date	Comparison of Providers					Provider Education ²	Delivery Channel				
	MD/ RN/ NP only ¹	Dietitian included	Other allied health	Lay person	Other Educator		One- on- one	Group	Telephone	Computer / Internet	Mail
Randomized Controlled Trials											
Bo et al., (2007)[19]		X				X(1)	X	X			
Kulzer et al., (2009)[29]			X					X			
Moore et al., (2011)[28]					X	X(1)	X	X			
Penn et al., (2009) [27]		X					X	X			X
Sakane et al., (2011)[26]	X	X					X	X	X		
Before and after cohort											
Bihan et al. (2009) [55]	X						X		X		
Kramer et al., (2009) [31]		X			X	X (2)		X			
Kramer et al. (2011)[30]		X				X (3)		X			
Saaristo et al., (2010) [24]	X	X					Varied X	X	X		X

¹ MD = physician, RN = registered nurse, NP = nurse practitioner

² Describes detail of provider education; where 1 = brief description, 2 = two to three sentence description, 3 = paragraph description

Table 4: Weight Changes in Relevant Prediabetes or Metabolic Syndrome Studies

				INTERVENTION GROUP					NET (Intervention-Control)	
				Baseline		Baseline-Post or F/U			NET Δ BMI	NET % WEIGHT LOSS
Author/Date	Overall QA	Intervention Length (mo.)	F/U (mo.)	N	Mean BMI	Mean Weight (kg)	Δ in BMI	% Weight Loss		
Randomized Controlled Trials										
Bo et al., (2007) [19]	Strong	12		169	29.7	81.7	0.3	0.9	0.9	3.2
Kulzer et al., (2009)[29]	Moderate		12	91	31	92.1	1.3	4.1	0.8	2.6
Moore et al. , (2011) [28]	Moderate	6		183	29.7	80.7	0.9	3.2	2.2	1.0
Penn et al., (2009) [27]	Weak	60		51	34.1	93.4		2.5		2.5
Sakane et al., (2011) [26]	Weak	6	36	123	24.8	64.9		2.8		0.6
Cohort – One Group										
Kramer et al. (2009) [31]	Weak	3	12	42	34.6	94.7		4.8		
Kramer et al. (2011) [30]	Weak		12	81	37.1	101.5	1.8	5.0		
Saaristo et al (2010) [24]	Weak		12							
Males				919	30.9	95.8	0.4	1.4		
Females				1879	31.6	83.8	0.4	1.3		

QA = quality assessment rating [15], mo = months, int= intervention, F/U= last follow-up measurement

Table 5: At Risk for Diabetes or Metabolic Syndrome Studies with no Clinically Relevant Changes or Excluded for Selection Bias

Author / Date	Weight /BMI ¹	A1C ¹	Lipids LDL-C ¹	SBP/DBP ¹	Disease Incidence, risk reversion, CVD risk	Comment
Absetz et al., 2007 [56]	x		x	x		
Almeida et al., 2010 [57]	x					
Avram et al 2011 [58]	x					
Boltri et al., 2007 [59]						No relevant outcomes
Botomino et al., 2008 [60]	x					
Christian et al., 2011[61]	x		x	x		
Kinmonth et al., 2008 [62]	x	x	x	x		
Laatikainen et al., 2007 [63]	x		x	x		
Makrilakis et al., 2010 [64]	x		x	x		
Mensink et al., 2003 [65]	x	x	x			
Nilsen et al., 2011 [66]	x	x		x		
Oldroyd et al., 2006 [67]	x		x			
Smith-Raye et al., 2009[68]						No relevant outcomes
Wadden et al., 2011[69]	xx		x	x		Not representative
Whittemore et al., 2009 [70]			x			
Yamashiro et al., 2010 [71]	B only	x	x	x		

¹ All studies bolded **xx** demonstrated clinically relevant weight loss ($\geq 3\%$ weight loss OR decrease of ≥ 1 BMI unit); glycated hemoglobin ($\geq 1\%$ decrease in A1C levels); LDL-cholesterol ($\geq 11\%$ decrease in LCL-C levels) and blood pressure [BP] ($\geq 4\%$ decrease in systolic [SBP] or diastolic [DBP]).

Additional files

Additional file 1 - Search Strategy (File name: Additional file 1 - Search Strategy.docx)

Additional file 2 – Abstract and Full Text Screening Tools (File name: Additional file 2 – Abstract and Full Text Screening Tools.docx)

Additional file 3 – Diabetes Studies (File name: Additional file 3 – Diabetes.docx)

Additional file 4 – Mixed Cardiovascular Risk Studies (File name: Additional file 4 – Mixed CVD Risk.docx)

Additional file 5 – Health Promotion or Weight Loss Studies (File name: Additional file 5 – Health

Promotion or Weight Loss.docx)

Additional file 6 – Hypertension Studies (File name: Additional file 6 – Hypertension.docx)

Additional file 7 – Dyslipidemia Studies (File name: Additional file 7 – Dyslipidemia.docx)

Additional file 8 – Pediatrics Studies (File name: Additional file 8 – Pediatrics.docx)

Additional file 9 – Complex Chronic Disease Studies (File name: Additional file 9 – Complex Chronic Disease.docx)

Additional file 10 – Pregnancy Studies (File name: Additional file 10 – Pregnancy.docx)

Additional file 11- Reviewed Studies (File name: Additional file 11 – references.docx)





Figure 1. Study Selection Process.

Figure 2. Location of Studies by Country.



Other countries (11% or 31 studies): Denmark 3 studies; France 3; Greece 3; Ireland 3; Norway 3; Belgium 2; Brazil 2; China 2; Switzerland 2; both Australia and New Zealand 1; Austria 1; Chile 1; Korea 1; Mexico 1; Singapore 1; Taiwan 1; Turkey 1.

Figure 3. Number of Studies by Disease/Condition Focus (n=280)

